Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa

Stock Information for Avalo Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avalo Therapeutics Inc.

Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Avalo Therapeutics Purchases Optional Milestone Buyout
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.